Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ABCL

ABCL - AbCellera Biologics Inc Stock Price, Fair Value and News

3.02USD-0.04 (-1.31%)Delayed

Market Summary

ABCL
USD3.02-0.04
Delayed
-1.31%

ABCL Alerts

  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

ABCL Stock Price

View Fullscreen

ABCL RSI Chart

ABCL Valuation

Market Cap

888.0M

Price/Earnings (Trailing)

-6.05

Price/Sales (Trailing)

24.81

EV/EBITDA

-5.28

Price/Free Cashflow

-6.96

ABCL Price/Sales (Trailing)

ABCL Profitability

EBT Margin

-471.19%

Return on Equity

-13%

Return on Assets

-10.04%

Free Cashflow Yield

-14.37%

ABCL Fundamentals

ABCL Revenue

Revenue (TTM)

35.8M

Rev. Growth (Yr)

-37%

Rev. Growth (Qtr)

8.44%

ABCL Earnings

Earnings (TTM)

-146.9M

Earnings Growth (Yr)

-1.25%

Earnings Growth (Qtr)

13.87%

Breaking Down ABCL Revenue

Last 7 days

-11.9%

Last 30 days

-17.0%

Last 90 days

-36.1%

Trailing 12 Months

-60.2%

How does ABCL drawdown profile look like?

ABCL Financial Health

Current Ratio

7.76

ABCL Investor Care

Shares Dilution (1Y)

1.84%

Diluted EPS (TTM)

-0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202435.8M000
2023373.6M261.7M149.9M38.0M
2022489.0M507.3M603.2M485.4M
2021431.2M447.7M443.8M375.2M
202067.0M122.4M177.8M233.2M
201900011.6M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AbCellera Biologics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 31, 2024
hansen carl l. g.
acquired
151,538
2.7
56,125
chief executive officer
Feb 26, 2024
hansen carl l. g.
acquired
151,538
2.7
56,125
chief executive officer
Dec 19, 2023
thermopylae holdings ltd.
gifted
-
-
-210,000
-
Nov 23, 2023
hansen carl l. g.
acquired
151,538
2.7
56,125
chief executive officer
Nov 08, 2023
montalbano john s.
bought
44,600
4.46
10,000
-
Nov 06, 2023
montalbano john s.
bought
92,800
4.64
20,000
-
Sep 22, 2023
hayden michael r
bought
98,200
4.91
20,000
-
Sep 12, 2023
lecault veronique
bought
103,800
5.19
20,000
chief operating officer
Aug 24, 2023
hansen carl l. g.
acquired
151,538
2.7
56,125
chief executive officer
Aug 08, 2023
hayden michael r
bought
177,000
5.9
30,000
-

1–10 of 50

Which funds bought or sold ABCL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-122,000
389,000
-%
May 24, 2024
Cetera Investment Advisers
new
-
103,633
103,633
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
67.75
63,066
255,066
0.03%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-59.38
-942,094
447,949
-%
May 16, 2024
B. Riley Wealth Advisors, Inc.
reduced
-46.15
-63,045
48,300
-%
May 15, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
sold off
-100
-857
-
-%
May 15, 2024
Aquatic Capital Management LLC
new
-
84,711
84,711
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
added
76.95
2,290,180
7,961,930
0.02%
May 15, 2024
BRANDYWINE MANAGERS, LLC
unchanged
-
-67,232
258,101
0.26%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-30.41
-16,074
19,814
-%

1–10 of 42

Are Funds Buying or Selling ABCL?

Are funds buying ABCL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABCL
No. of Funds

Unveiling AbCellera Biologics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
baker bros. advisors lp
7.9%
22,909,753
SC 13G
Feb 13, 2024
hansen carl l. g.
20.6%
60,740,524
SC 13G/A
Jan 29, 2024
baillie gifford & co
8.29%
24,044,796
SC 13G/A
Apr 24, 2023
thiel peter
4.99%
14,360,427
SC 13D/A
Feb 13, 2023
capital world investors
3.3%
9,327,493
SC 13G/A
Feb 06, 2023
hansen carl l. g.
20.4%
58,993,307
SC 13G/A
Jan 18, 2023
baillie gifford & co
6.88%
19,696,735
SC 13G
Feb 14, 2022
dcvc bio, l.p.
2.6%
7,305,761
SC 13G/A
Feb 14, 2022
viking global investors lp
0.0%
0
SC 13G/A
Feb 11, 2022
capital world investors
7.8%
22,051,703
SC 13G

Recent SEC filings of AbCellera Biologics Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
May 07, 2024
8-K
Current Report
May 07, 2024
10-Q
Quarterly Report
Apr 29, 2024
DEFA14A
DEFA14A
Apr 29, 2024
DEF 14A
DEF 14A
Apr 29, 2024
ARS
ARS

Peers (Alternatives to AbCellera Biologics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.85
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.9M
2.1M
16.67% 230.00%
-0.86
7.61
-13.45% 69.54%

AbCellera Biologics Inc News

Latest updates
MarketBeat17 Jun 202402:01 pm
The Motley Fool13 Jun 202409:40 am

AbCellera Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue8.4%10.009.007.0010.0016.0022.0010146.003171395.0028.002032089.0011.005.00-
Operating Expenses-13.8%65.0075.0061.0061.0077.0059.0064.0054.0092.0058.0034.0035.0045.0047.0011.0012.007.00-
  S&GA Expenses8.5%3.003.003.004.004.003.003.003.002.002.001.001.003.002.001.001.000.00-
  R&D Expenses-19.2%39.0049.0038.0036.0053.0028.0027.0027.0026.0017.0017.0015.0012.009.007.009.004.00-
EBITDA Margin-2.9%-4.05*-3.94*-0.84*-0.16*-0.03*0.55*0.62*0.59*0.62*0.62*0.68*0.72*------
Income Taxes-47.2%-2.14-1.45-10.67-7.48-8.04-1.5220.00-0.1062.0025.00-3.590.0044.00-----
Earnings Before Taxes12.0%-42.75-48.60-39.28-38.00-48.15-31.4147.00-6.8923185.00-24.97-2.07161156-2.697.00-2.09-
EBT Margin-3.0%-4.71*-4.58*-1.05*-0.27*-0.11*0.49*0.59*0.56*0.59*0.58*0.65*0.70*------
Net Income13.9%-40.61-47.15-28.61-30.53-40.11-29.8927.00-6.7816960.00-21.38-2.321172.00-2.697.00-2.09-
Net Income Margin-6.6%-4.10*-3.85*-0.86*-0.28*-0.13*0.33*0.41*0.39*0.42*0.41*0.21*0.25*------
Free Cashflow-93.4%-65.85-34.04-20.44-7.30-59.0519.00-13924286.00-26.14-14.51121------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-1.7%1,4631,4881,5121,5371,4981,5411,5521,5941,5921,3191,1731,1521,1291,006
  Current Assets-6.7%8148729209319411,0251,0461,1441,174930804864908813
    Cash Equivalents-7.3%124133172180218387397816571501518793686594
  Net PPE---27726023321720114912211292.0087.0035.0018.00
  Goodwill0%48.0048.0048.0048.0048.0048.0048.0048.0048.0048.0049.0032.0032.0032.00
Liabilities-0.8%333336329342289308302381385293219184171175
  Current Liabilities-11.9%10511911011990.0011810622121312150.0070.0088.00103
Shareholder's Equity-1.9%1,1301,1521,1831,1951,2091,2331,2501,2131,2081,026953968957831
  Retained Earnings-14.5%239280327356386426456429436268208229231114
  Additional Paid-In Capital5.7%12812110996.0082.0074.0064.0056.0045.0035.0027.0022.0015.006.00
Shares Outstanding-1.0%291294287287288287285285284276274272--
Float----1,464---2,404,552---3,794,989--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-112.7%-41,708-19,611-10619,903-44,06330,912-126,786273,015100,219-16,712-5,932157,683109,5451,278-3,80125,977-764-
  Share Based Compensation5.8%17,40916,44815,86216,39915,47413,32311,75412,11312,2919,0387,7088,4735,4274,6221,9326061,237-
Cashflow From Investing223.0%29,910-24,323-12,786-34,390-149,609-17,063-281,994-27,197-26,371-1,149-269,626-45,633-15,839-108,182-3,885-2,130-5,583-
Cashflow From Financing-24.8%2,8313,7656,630419-458349-19.001,173-3,1311,834898-5,075-1,543609,939-14,37034687,738-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ABCL Income Statement

2024-03-31
Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 9,954$ 12,192
Operating expenses:  
Research and development[1]39,28752,647
Sales and marketing[1]3,3653,771
General and administrative[1]17,35215,134
Depreciation and amortization4,8445,514
Total operating expenses64,84877,066
Loss from operations(54,894)(64,874)
Other (income) expense  
Interest income(10,401)(9,759)
Grants and incentives(3,275)(3,374)
Other1,529(3,593)
Total other (income)(12,147)(16,726)
Net loss before income tax(42,747)(48,148)
Income tax recovery(2,137)(8,038)
Net loss(40,610)(40,110)
Foreign currency translation adjustment(96)(630)
Comprehensive loss$ (40,706)$ (40,740)
Net loss per share  
Basic (USD per share)$ (0.14)$ (0.14)
Diluted (USD per share)$ (0.14)$ (0.14)
Weighted-average common shares outstanding  
Basic (in shares)292,723,901287,767,136
Diluted (in shares)292,723,901287,767,136
Research fees  
Revenue:  
Total revenue$ 9,774$ 10,570
Licensing revenue  
Revenue:  
Total revenue180372
Milestone payments  
Revenue:  
Total revenue$ 0$ 1,250
[1]Exclusive of depreciation and amortization

ABCL Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 123,572$ 133,320
Marketable securities574,451627,265
Total cash, cash equivalents, and marketable securities698,023760,585
Accounts and accrued receivable34,41930,590
Restricted cash25,00025,000
Other current assets56,50655,810
Total current assets813,948871,985
Long-term assets:  
Property and equipment, net306,081287,696
Intangible assets, net118,736120,425
Goodwill47,80647,806
Investments in equity accounted investees71,59265,938
Other long-term assets104,93394,244
Total long-term assets649,148616,109
Total assets1,463,0961,488,094
Current liabilities:  
Accounts payable and other current liabilities42,88749,580
Contingent consideration payable51,43150,475
Deferred revenue10,56518,958
Total current liabilities104,883119,013
Long-term liabilities:  
Operating lease liability68,07971,222
Deferred revenue8,5708,195
Deferred government contributions110,57995,915
Contingent consideration payable5,0634,913
Deferred tax liability30,27430,612
Other long-term liabilities5,7355,906
Total long-term liabilities228,300216,763
Total liabilities333,183335,776
Commitments and contingencies
Shareholders' equity:  
Common shares: no par value, unlimited authorized shares at December 31, 2023 and March 31, 2024: 290,824,970 and 293,621,312 shares issued and outstanding at December 31, 2023 and March 31, 2024, respectively764,562753,199
Additional paid-in capital127,990121,052
Accumulated other comprehensive loss(1,816)(1,720)
Accumulated earnings239,177279,787
Total shareholders' equity1,129,9131,152,318
Total liabilities and shareholders' equity$ 1,463,096$ 1,488,094
ABCL
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
 CEO
 WEBSITEabcellera.com
 INDUSTRYBiotechnology
 EMPLOYEES590

AbCellera Biologics Inc Frequently Asked Questions


What is the ticker symbol for AbCellera Biologics Inc? What does ABCL stand for in stocks?

ABCL is the stock ticker symbol of AbCellera Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbCellera Biologics Inc (ABCL)?

As of Tue Jun 18 2024, market cap of AbCellera Biologics Inc is 888.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers. The fair value of AbCellera Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbCellera Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABCL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbCellera Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ABCL is over valued or under valued. Whether AbCellera Biologics Inc is cheap or expensive depends on the assumptions which impact AbCellera Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABCL.

What is AbCellera Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, ABCL's PE ratio (Price to Earnings) is -6.05 and Price to Sales (PS) ratio is 24.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABCL PE ratio will change depending on the future growth rate expectations of investors.